Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Palvella Therapeutics ( (PVLA) ) has provided an update.
On March 31, 2026, Palvella Therapeutics reported its full-year 2025 results and detailed significant clinical and corporate progress, highlighted by positive Phase 3 SELVA data in microcystic lymphatic malformations announced in February 2026 and positive Phase 2 TOIVA results in cutaneous venous malformations in December 2025. The company is preparing an NDA submission for QTORIN rapamycin in microcystic LMs in the second half of 2026, aims for a potential first FDA approval in the first half of 2027, and is advancing multiple new trials across angiokeratomas and DSAP while expanding indications from its QTORIN platform.
Palvella closed an upsized public equity offering in February 2026, lifting pro forma cash to about $274 million as of December 31, 2025 and providing funding to accelerate U.S. launch readiness and broader pipeline development. Full-year 2025 R&D and G&A expenses rose sharply to $22.8 million and $15.8 million, respectively, driving a wider net loss of $41.7 million, as the company invested in late-stage trials, manufacturing, headcount and public-company infrastructure to support its transition toward commercialization in rare dermatologic diseases.
The most recent analyst rating on (PVLA) stock is a Buy with a $270.00 price target. To see the full list of analyst forecasts on Palvella Therapeutics stock, see the PVLA Stock Forecast page.
Spark’s Take on PVLA Stock
According to Spark, TipRanks’ AI Analyst, PVLA is a Neutral.
The score is held down primarily by weak financial performance (no current revenue, ongoing losses, and persistent cash burn) and bearish technical signals. Offsetting this, corporate events are notably positive with encouraging Phase 2 data and clear near-term clinical/regulatory catalysts, but this does not fully overcome the current fundamentals and trend.
To see Spark’s full report on PVLA stock, click here.
More about Palvella Therapeutics
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel topical therapies for serious, rare skin diseases and vascular malformations that currently lack U.S. Food and Drug Administration-approved treatments. Its pipeline centers on its proprietary QTORIN platform, including QTORIN rapamycin and QTORIN pitavastatin, targeting mTOR- and mevalonate pathway-driven dermatologic conditions with significant unmet medical need in the U.S. market.
Average Trading Volume: 309,760
Technical Sentiment Signal: Buy
Current Market Cap: $1.51B
Find detailed analytics on PVLA stock on TipRanks’ Stock Analysis page.